Why Surgical Science Sweden (OM:SUS) Is Down 54.0% After Intuitive Cancels Key Licensing Agreement

• In late November 2025, Surgical Science Sweden AB announced that Intuitive canceled their Memorandum of Understanding and shifted back to their prior agreement, with the company warning it will not meet its previously stated 2026 financial targets.
• This decision is projected to reduce Surgical Science Sweden’s license revenues by approximately SEK 60–90 million in 2026, highlighting the company’s exposure to fluctuations in large partner relationships.
• To assess the impact of Intuitive’s contract cancellation on Surgical Science Sweden, we’ll explore how this affects expectations for future license revenue streams.

These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Surgical Science Sweden Investment Narrative Recap

To be a shareholder in Surgical Science Sweden, you need to believe that demand for medical simulation and robotic surgery training will steadily increase and that the company's ability to build and maintain strong recurring licensing partnerships is intact. The recent decision by Intuitive to cancel the Memorandum of Understanding could directly impact the most important short-term catalyst, license revenue growth, while also reinforcing the current biggest risk: dependence on a small number of large OEM customers. Among the recent announcements, the January 2024 integration of Surgical Science’s simulation software into all Intuitive da Vinci 5 systems stands out. This highlights the ongoing partnership and suggests that, even with changes to specific agreements, collaboration in simulation technology remains a core part of the company’s business and potential future catalysts. In contrast, what some investors might not fully appreciate is how a single partner’s shift can quickly reshape both revenue expectations and near-term share price performance...

Read the full narrative on Surgical Science Sweden (it's free!)

Surgical Science Sweden's outlook anticipates SEK1.6 billion in revenue and SEK479.8 million in earnings by 2028. This is based on an annual revenue growth rate of 20.3% and a SEK387.4 million increase in earnings from the current level of SEK92.4 million.

Uncover how Surgical Science Sweden's forecasts yield a SEK77.60 fair value, a 129% upside to its current price.

Exploring Other Perspectives

Fair value estimates from four Simply Wall St Community members for Surgical Science Sweden range from SEK77.60 to SEK188.34 per share. With recent events highlighting customer concentration risks, be sure to consider multiple perspectives before deciding your next steps.

Explore 4 other fair value estimates on Surgical Science Sweden - why the stock might be worth just SEK77.60!

Build Your Own Surgical Science Sweden Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Surgical Science Sweden research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Surgical Science Sweden research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Surgical Science Sweden's overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 35 companies in the world exploring or producing it. Find the list for free.
• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com